News | February 10, 2008

Minimally Invasive Vascular Occlusion Device for PDA Cleared in Europe

February 11, 2008 – A new minimally invasive vascular occlusion device designed to close a patent ductus arteriosus (PDA) received European CE Mark approval.

AGA Medical Corp. (AGA) announced today it received approval for the AMPLATZER Duct Occluder II (ADO II), a self-expanding nitinol mesh device designed to occlude or close PDA, a type of congenital heart defect that occurs when a blood vessel called the ductus arteriosus fails to close after birth.

The device has two retention disks positioned on either side of the duct and connected by a waist. The ADO II is designed with a screw mechanism for attachment to the deployment cable that allows the device to be withdrawn and repositioned, if necessary, prior to release from the cable.

For more information: www.amplatzer.com


Additional Content

News | Structural Heart Occluders

June 20, 2024 — atHeart Medical, a medical device company establishing a new standard of care for atrial septal defects ...

Home June 20, 2024
Home
News | Structural Heart Occluders

July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the ...

Home July 14, 2023
Home
News | Structural Heart Occluders

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...

Home May 05, 2022
Home
News | Structural Heart Occluders

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

Home October 04, 2021
Home
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
Subscribe Now